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ARTICLE OPEN
Association between age of cannabis initiation and gray matter
covariance networks in recent onset psychosis
Nora Penzel1,2, Linda A. Antonucci2,3, Linda T. Betz 1, Rachele Sanfelici2,4, Johanna Weiske2, Oliver Pogarell2, Paul Cumming5,6,
Boris B. Quednow 7, Oliver Howes8,9,10,11, Peter Falkai2, Rachel Upthegrove12, Alessandro Bertolino13, Stefan Borgwardt 14,15,
Paolo Brambilla 16,17, Rebekka Lencer 15,18,19, Eva Meisenzahl20, Marlene Rosen1, Theresa Haidl1, Lana Kambeitz-Ilankovic1,2,
Stephan Ruhrmann 1, Raimo R. K. Salokangas 21, Christos Pantelis 22, Stephen J. Wood12,23,24, Nikolaos Koutsouleris2,8,25,
Joseph Kambeitz 1 and the PRONIA Consortium
Cannabis use during adolescence is associated with an increased risk of developing psychosis. According to a current hypothesis,
this results from detrimental effects of early cannabis use on brain maturation during this vulnerable period. However, studies
investigating the interaction between early cannabis use and brain structural alterations hitherto reported inconclusive findings. We
investigated effects of age of cannabis initiation on psychosis using data from the multicentric Personalized Prognostic Tools for
Early Psychosis Management (PRONIA) and the Cannabis Induced Psychosis (CIP) studies, yielding a total sample of 102 clinically-
relevant cannabis users with recent onset psychosis. GM covariance underlies shared maturational processes. Therefore, we
performed source-based morphometry analysis with spatial constraints on structural brain networks showing significant alterations
in schizophrenia in a previous multisite study, thus testing associations of these networks with the age of cannabis initiation and
with confounding factors. Earlier cannabis initiation was associated with more severe positive symptoms in our cohort. Greater gray
matter volume (GMV) in the previously identified cerebellar schizophrenia-related network had a significant association with early
cannabis use, independent of several possibly confounding factors. Moreover, GMV in the cerebellar network was associated with
lower volume in another network previously associated with schizophrenia, comprising the insula, superior temporal, and inferior
frontal gyrus. These findings are in line with previous investigations in healthy cannabis users, and suggest that early initiation
of cannabis perturbs the developmental trajectory of certain structural brain networks in a manner imparting risk for psychosis
later in life.
Neuropsychopharmacology (2021) 0:1–10; https://doi.org/10.1038/s41386-021-00977-9
INTRODUCTION
Schizophrenia (SZ) is viewed as a neurodevelopmental disorder
wherein disruptions in the typical trajectory of brain development
interact with environmental factors to precipitate psychosis [1]. In
this scenario, adolescence is an important time window for the
early identification of risk and timely intervention [2], as the
adolescent brain undergoes ongoing maturational processes,
which include synaptic pruning [3] and maturation of neuro-
transmitter systems, including the endogenous cannabinoid
system [3]. Exposure to environmental stressors during this critical
maturation stage might interfere with the normal developmental
trajectory of gray and white matter (GM, WM), thereby increasing
the risk for developing SZ [1, 4]. One of the most important
environmental risk factors for SZ is heavy cannabis use [5, 6].
Given recent international changes in the legality of cannabis use,
the investigation of possible harmful effects of the substance on
risk groups assumes a new relevance [7]. Cannabis use is
associated with structural GM changes in brain regions
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consistently associated with psychosis [8, 9], including the
hippocampus, amygdala, as well as striatal, prefrontal cortical,
and cerebellar regions [5, 10]. These GM alterations can be
discerned in cannabis-using patients with psychosis [11], prodro-
mal individuals [12] and in healthy individuals who use cannabis
regularly [13].
Previous studies indicate that the effect of cannabis on brain
structure might be moderated by the age at initiation of heavy use
[14]. Healthy cannabis users who had begun to consume cannabis
before 16–17 years of age show GM volume (GMV) reductions in
the frontal lobe and the parahippocampal gyrus [5, 14, 15] and
GMV increases in the cerebellum [13].
Despite this background, other studies of cannabis use in
adolescents [16, 17] and retrospective studies investigating the
structural-anatomic effects of age of cannabis initiation in adults
[18] do not report alterations in GMV. Thus, results focusing on the
impact of age of cannabis initiation on brain structure remain
inconclusive and focus on the effects of age of initiation in healthy
individuals, thereby not considering possible specific effects of the
age of cannabis initiation on the earlier trajectory of brain
development in psychotic individuals [19]. To date, such studies in
psychosis have only investigated the general impact of cannabis
use on brain structure. Previous investigations have used
univariate approaches, such as region-of-interest analysis or
voxel-based morphometry (VBM) [20], thereby neglecting from
consideration the highly interconnected nature of the brain
[21, 22]. Especially in terms of brain maturation, this interconnec-
tivity plays an important role, since the covariance between brain
voxels is thought to reflect shared maturational processes and
functional specialization, which might be disrupted in parallel in
the face of environmental stressors [23–25]. Multivariate, data-
driven approaches such as source-based morphometry (SBM)
represent a well-established alternative approach that accommo-
dates the covariance between brain voxels [26, 27]. In SBM, an
independent component analysis (ICA) identifies brain networks
characterized by covariation in GMV [26, 27]. The approach thus
enables the comparison of independent structural brain networks
between different groups [26, 27]. By maximizing the indepen-
dence of isolated brain networks, SBM is a powerful technique for
separating scanner noise (e.g., often reported site-effects) from
true signals [28], and is thought to unify structural regions that
have comparable maturational trajectories. The recently intro-
duced semi-blind ICA algorithms, such as group information
guided ICA (GIG-ICA), incorporate prior information in the form of
spatial constraints [29, 30], thus exploiting the advantages of data-
driven approaches, while focusing the analysis on networks of
interest [29].
In the current study, we aimed to investigate the effect of the
age of cannabis initiation among patients with recent onset
psychosis (ROP) on structural networks that are already reliably
associated with SZ and thus are of relevance for the pathology of
the disease. Due to the compilation of data from multiple sites, we
concentrated our analyses on networks that are robustly
associated with alterations in patients with SZ across sites. A
recent study by Gupta et al. [9] merged data from nine different
studies and identified four structural components of abnormal
GMV covariation with high reproducibility. We hypothesized that
the age of cannabis use initiation in ROP patients is associated
with alterations in SZ-related GM networks, including brain
regions previously associated with early initiation of cannabis
use in healthy individuals (e.g., frontal areas and cerebellum). We
aimed to advance the present knowledge of cannabis effects on
the four components reported for SZ patients: (i) superior
temporal gyrus, inferior frontal gyrus and insula, (ii) superior
frontal gyrus, middle frontal, and medial frontal gyrus, (iii)
brainstem, and (iv) inferior semilunar lobule and cerebellar tonsils.
Previous work indicated that GM concentration was reduced in
the frontal, temporal, and cerebellar components (i, ii, iv) and
increased in the brainstem component, (iii) in SZ patients
compared to controls [9]. Further, we adopt a network-based
perspective to explore the associations of the age of cannabis
initiation on the psycho- and neuropathology of psychosis. We
predicted that this approach might reveal potential pathways
whereby cannabis use patterns might propagate to positive
psychotic symptoms and/or development of neurostructural
perturbations [31].
MATERIALS AND METHODS
Study design and population
We analyzed data of 102 patients with ROP aged 15–40 years from
two studies, the multisite longitudinal PRONIA study (www.pronia.
eu, German Clinical Trials Register identifier DRKS00005042 [32])
and the ongoing, monocentric, longitudinal Cannabis Induced
Psychosis (CIP) study, after harmonizing the study protocols
(Supplementary Fig. 1). CIP patients were recruited at the
Department of Psychiatry at the Ludwig Maximilian’s University
of Munich, while ROP cases included in PRONIA were recruited at
eight European sites (see [32]). ROP experienced an affective or
non-affective psychotic episode within the past 24 months and
present within the 3 months preceding study entry. Psychiatric
diagnoses were obtained by trained clinical raters, based on the
Structured Clinical Interview for DSM-IV disorders [33]. To focus
our analysis on ROP patients who had a clinically-relevant
comorbid cannabis use, we imposed additional inclusion criteria,
defined by (i) cannabis use preceding the onset of psychotic
symptoms by no more than 2 weeks as defined in the
International Classification of Diseases, 10th Revision, criteria for
substance-induced psychosis [34], and/or (ii) a lifetime cannabis
abuse or dependence [33]. Participants were only included when
their age of cannabis initiation was recorded (Supplementary
Information for detailed inclusion and exclusion criteria, Supple-
mentary Fig. 5). Fourteen subjects from the PRONIA study had to
be excluded due to the lack of this information. Subjects with
missing data for age of cannabis initiation had significantly more
severe symptoms, were more likely to have cannabis abuse or
dependency use, and there was an interaction with site
(Supplementary Table 3).
All individuals from PRONIA underwent baseline assessment
between 2014 and 2019 and were followed for up to 36 months.
The CIP recruitment took place from December 2016 until May
2019 and the follow-up period was 9 months. Most assessments
overlapped between the two studies in that both studies included
multimodal imaging, a neuropsychological assessment and a
clinical protocol (assessments are listed in Supplementary Table 1).
Prior to their inclusion in the study, all participants provided
written informed consent (either personally or through a legal
guardian if below the age of 18). Studies were approved at their
respective sites by the local research ethics committees.
Assessment of cannabis consumption
The age of initiation and other cannabis intake measures were
assessed in a clinical interview. Initiation age entered all models as
a continuous variable (Supplementary Fig. 3 for distribution of age
of cannabis initiation). For the purpose of tabular presentation, we
divided the study sample into early- and late-onset users, based
on the median of 17 years (Supplementary Table 4 for age of
cannabis initiation as continuous variable) [15].
Acquisition protocol and preprocessing pipeline of structural MRI
A harmonized protocol for the acquisition of structural MRI data
was used at all sites. For preprocessing, we used the open-source
CAT12 toolbox (version r1155; http://dbm.neuro.uni-jena.de/
cat12/), which is an extension of SPM12 running in MATLAB
2018a. First, all images were segmented into GM, WM, and
cerebrospinal fluid, normalized to stereotactic space of Montreal
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Neurological Institute (MNI-152) and multiplied with the Jacobian
determinants obtained during registration to derive the final GMV
maps. After quality control (Supplementary Information), we
regressed age and sex effects voxel-wise, as previous studies
have shown that regressing for such effects prior to SBM analysis
increases sensitivity to group differences [28]. Subsequently,
images were realigned to a two mm voxel resolution and
smoothed with a ten mm (full-width at half maximum) Gaussian
kernel [9] (Supplementary Table 5).
Source-based morphometry
SBM analysis was conducted by applying GIG-ICA to sMRI data
using the GIFT toolbox (http://mialab.mrn.org/software/gift/) in
MATLAB 2020. Here, GIG-ICA was optimized to identify four
independent components with maximum similarity to the four
reference components (RCs) that had previously been associated
with SZ, with high reproducibility between sites [9]. To account for
study-specific scanner effects, we used a strategy based on G-
theory for voxel selection of the RCs [32], employing a threshold of
>0 to exclude voxels showing only between-site but no inter-
subject-variation [35] (Fig. 1, Supplementary Information).
In the first step, GM images were converted to one-
dimensional row vectors and concatenated across participants.
After excluding outliers with extremely high source variability
that might otherwise drive spurious significant results (Supple-
mentary Information), we derived a 102-by-175,000 GMV voxel
matrix. This matrix was decomposed into a source matrix and a
mixing matrix. The mixing matrix represents loadings, i.e., the
weights of individual participants on each component. The
source matrix, represents the relationship between each voxel
and the components (Fig. 1). This decomposition simultaneously
maximizes the correspondence to the RCs and the indepen-
dence of the components from each other such that each row in
the source matrix is maximally independent from the others. To
match the components derived from this study with the
established RCs and to test their validity, we used a stepwise
procedure as described previously [36] (Supplementary Informa-
tion). Based on that previous literature [36], components from
the current study (COIs) with a correlation r > 0.5 with a RC were
included in subsequent analyses. Additionally, we utilized GIG-
ICA on a subsample restricted to cases of schizophrenia
spectrum disorder (SSD) to enhance comparability with the
sample in which the RCs were generated and to further reduce
heterogeneity in terms of severity of symptoms and diagnoses.
To test for sex-specific effects of cannabis use initiation on brain
structure we recalculated the components based on male
subjects only. Due to the lower sample size, this analysis was
not possible in females.
Voxel-based morphometry. To maximize comparability with pre-
vious studies, we performed an additional VBM analysis (Supple-
mentary Information).
Fig. 1 For the analysis pipeline based on GIG-ICA four components from a previous study of SCZ [9] were selected as reference
components and thresholded using the G-theory mask (derived from six healthy traveling subjects) to correct for scanner-specific
effects. We extracted components using GIG-ICA by maximizing the non-Gaussianity and simultaneously minimizing the distance to the
reference components.
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Statistical analysis
We performed all further statistical analyses using R language for
statistical computing, version 3.6.2 [37]. To analyse differences in
GMV covariation due to age of cannabis initiation, we investigated
participants’ loading coefficients, employing a linear mixed effects
model in the R-package “lmerTest” [38] with loading coefficients
as dependent variables. Age of cannabis initiation was modeled as
a fixed effect, while the factor “site” was modeled as a random
effect. In our analysis of ICA components, larger loading
coefficients indicate a stronger weighting of the spatial pattern
in the individuals [9, 26]. Higher loading coefficients, coupled with
a positive spatial component, shall be interpreted as greater GMV
in this component [9]. Effect sizes in terms of R2 were calculated
with the R-package “r2glmm” as proposed recently [39]. To assess
Table 1. Demographics and clinical data.
Early (<17) Late (17+) df T/Z/X2 p value
Samples and study variables
Sample sizes 58 44
CIP (%) 29 (49.2) 15 (34.1) 1 1.970 0.160
Age [mean (SD) years] 24.1 (4.1) 23.4 (4.0) 94 0.820 0.413
Sex [F (%)] 11 (19.0) 12 (27.3) 1 0.571 0.450
Sample size per site 7 22.690 0.002
Munich (%) 45 (77.6) 25 (56.8)
Milan Niguarda (%) 0 (0) 6 (13.6)
Basel (%) 8 (13.8) 3 (6.8)
Cologne (%) 2 (3.4) 3 (6.8)
Birmingham (%) 3 (5.2) 0 (0)
Turku (%) 0 (0) 5 (11.4)
Udine (%) 0 (0) 1 (2.3)
Düsseldorf (%) 0 (0) 1 (2.3)
Cannabis use
Lifetime history of DSM-IV cannabis use disorder [N (%)] 2 1.030 0.597
Cannabis abuse (%) 24 (41.4) 23 (22.5)
Cannabis dependency (%) 25 (24.5) 16 (15.7)
Initiation age [mean (SD) years] 14.9 (1.2) 19.8 (3.2) 51.400 −9.61 <0.001
Cumulative months lifetime [mean (SD) months] 58.1 (40. 5) 25.2 (24.9) 55.990 3.831 <0.001
Duration of heaviest use [mean (SD) days] 822.2 (873.6) 389.7 (379.1) 70.637 3.197 0.006
Level of use in the heaviest use period (%) 2 2.889 0.236
>10 times per month/dependency 49 (48.0) 35 (34.3)
<10 times per month 5 (5.9) 6 (5.9)
Only once 3 (2.9) 0 (0)
Duration since last use [mean (SD) days] 369.1 (1151.8) 276.6 (661.6) 87.127 0.489 0.626
Level of use in the last 3 months—cumulative frequency (%) 7 3.106 0.875
0 times 16 (15.7) 16 (15.7)
1–5 times 3 (2.9) 4 (3.9)
6–10 times 4 (3.9) 2 (2.0)
11–15 times 3 (2.9) 2 (2.0)
16–20 times 2 (2.0) 2 (2.0)
21–30 times 2 (2.0) 1 (1.0)
>30 times 14 (13.7) 6 (5.9)
Psychopathology [mean (SD)]
Positive and negative syndrome scale—positive 20.7 (5.3) 17.8 (6.9) 72.541 2.293 0.025
Positive and negative syndrome scale—negative 14.7 (5.47) 14.4 (5.8) 83.919 1.031 0.306
Positive and negative syndrome scale—general 35.0 (8.3) 33.2 (8.3) 81.319 0.231 0.818
Onset age of psychotic disorder 23.6 (4.2) 23.3 (3.8) 93.776 0.399 0.691
Years between first cannabis use initiation and attenuated psychotic symptoms—years
[mean (SD)]
7.5 (4.6) 3.3 (4.0) 66.025 4.175 <0.001
Years between initiation of heaviest cannabis use and attenuated psychotic symptoms—
years [mean (SD)]
2.6 (3.9) 1.4 (2.6) 70.393 1.524 0.132
Medication [mean (SD)]
Currently treated (%) 37 (63.8) 28 (63.6) 1 <0.001 1
Chlorpromazine equivalent (cumulative lifetime) 4764.1 (7445.2) 4903.0 (7872.9) 87.852 −0.089 0.929
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the possible impact of certain confounding factors typically
reported to effect GMV, we estimated the same model with
addition of the duration of heaviest use, the chlorpromazine
equivalent cumulative in lifetime, current medication use (yes/no)
[40, 41], alcohol abuse (yes/no) [42] and the duration of illness [43]
(all variables modeled as fixed factors). All p values were corrected
for multiple testing using the false discovery rate (FDR) with a
threshold of pFDR < 0.05 [44]. Associations between age of
cannabis use initiation and COI loadings were tested indepen-
dently with cognition (Supplementary Information).
Exploratory network analysis
We fitted a network in the form of a Gaussian Graphical Model
(using the R-package “qraph”, version 1.6. 3 [45]), including all COI
loadings passing the inclusion threshold, initiation age, duration of
use, and positive psychotic symptoms in the last 7 days measured
by the Positive and Negative Syndrome scale (PANSS) [46]. In such
a network, undirected connections between two variables
represent pairwise partial correlations after conditioning on all
other variables [47]. These connections are interpreted as
predictive effects between two variables, which cannot be
explained by any other variable in the network. We determined
the optimal network model by using stepwise, unregularized




ROP patients with early (<17 years) and late (≥17 years) cannabis
use initiation showed no differences in sociodemographic
variables (Table 1 and Supplementary Table 2). Early users had a
significantly longer mean duration of cannabis use compared to
late users, had more severe positive psychotic symptoms and
significantly longer duration between the cannabis use initiation
and first attenuated psychotic symptoms measured by Standar-
dized Interview for the assessment of Prodromal Symptoms
(modified version 5.0) (any SIPS-P item ≥3) [48]. Patients with
early- and late-initiation of cannabis did not differ for cumulative
frequency of cannabis use in the previous 3 months, prevalence of
a SCID lifetime diagnosis of cannabis abuse or dependency,
prevalence of lifetime alcohol abuse, other drugs taken or in the
cumulative dose or current intake of antipsychotics.
Creation of the components of interest (COIs)
SMRI data of 102 ROP patients with history of clinically-relevant
cannabis use were decomposed into four components based on
independence and correspondence to the RCs [9]. Brain regions of
all four COIs were identified from the Talairach Daemon (http://
www.talairach.org/daemon.html) and visualized with the MRI-
croGL software (McCausland Center for Brain Imaging, University
of South Carolina; https://www.nitrc.org/projects/mricrogl/). A
minimum z-threshold was set to |>2.5| and a maximum
z-threshold was derived from [9] for each component indepen-
dently (Fig. 2).
Three of the four COIs passed the threshold of r > 0.5 for
correspondence to the RCs and were included in further analyses,
while COI-3, which comprises mainly the brainstem, was excluded
(r= 0.38, p < 0.001).
COI-2 had the highest correlation with RC-2 and encompassed
mainly the superior, medial, and middle frontal gyrus (r= 0.712,
p < 0.001, Table 2). The next highest correlation was between COI-
1 and RC-1 (r= 0.671, p < 0.001). COI-1 comprised mainly the
superior temporal, precentral, frontal and parahippocampal gyrus
and insula (Table 2). COI-9 had a moderate correlation with RC-9
(r= 0.59, p < 0.001), although many voxels had to be excluded
from RC-9 due to study-specific scanner effects (41%). This
component mainly comprised cerebellar regions (Table 2). The
assignment between COIs and RCs remained similar in our control
subanalyses restricted to the male and SSD groups, except that
the correlation coefficient was lower (Supplementary Information).
Relationship between the components and cannabis use patterns
We found that higher loading coefficients for COI-9 were
significantly associated with earlier cannabis initiation, after
correcting for site (t102=−2.762, pFDR= 0.02). In combination
with the predominantly positive component, this implies that
increased GMV in cerebellar regions is associated with an earlier
initiation of cannabis use. Adding several hypothesized confound-
ing covariates had slight effects on the results, significantly higher
loading coefficients were still associated with an earlier initiation
(t80=−3.00, pFDR= 0.01), with the difference that the random
effect “site” became significant in this model (t80= 2.62, pFDR=
0.03). No other covariates significantly correlated with the loading
coefficients of any of the components. Age of cannabis initiation
explained 7.9% of the 10% of the variance explained in the full
model. Initiation age did not show any significant effect on the
Fig. 2 Cerebral mapping of the reference components and the four components from the current study, all thresholded at |z| > 2.5. The
reference components are thresholded with the G-theory mask.
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other components (Fig. 3). Cognitive performance was neither
associated with the age of cannabis initiation nor with the
cerebellar loadings (Supplementary Information). Subsequent
control analyses, in the SSD and the male subgroups showed
comparable effects (Supplementary Information).
Complementary network analysis
The network (Fig. 3) illustrates the connections between the
overall severity of positive symptoms at time of assessment
measured by PANSS, age of cannabis initiation, duration of use,
and COI-2, COI-1, and COI-9. From 15 possible edges, only four
remained in the unregularized model selection procedure. Age of
cannabis initiation was negatively associated with positive
symptoms measured by the PANSS, age of initiation was
negatively associated with the duration of cannabis use, age of
initiation was negatively associated with COI-9, whereas COI-9
was negatively associated with COI-1. These associations are
specific, i.e., they remain after all other associations have been
taken into account. Bootstrapping analyses showed that edges
retained in the final model were also present in the majority of
bootstrapped networks (Supplementary Fig. 6). However, when
testing case subsetting, the edges were not stable (Supplemen-
tary Fig. 7).
Voxel-based morphometry. We did not find any significant
volume difference associated with the age of cannabis initiation
at the proposed threshold of FWE—p < 0.05. However, at an
uncorrected threshold (p < 0.005, k= 5) the direction of our VBM
analyses was in line with our findings in SBM (Supplementary
Table 10 and Supplementary Fig. 8).
DISCUSSION
To the best of our knowledge, this is the first study investigating
the effects of the age of cannabis use initiation on GMV in
patients with ROP. Moreover, for the first time, we employed a
GIG-ICA to investigate cannabis use history on structural brain
networks previously identified in SZ [9]. Our results link the
initiation of cannabis use during adolescence to long-lasting
structural effects, manifesting in the present finding of greater
GMV in patients with an earlier age of cannabis initiation.
Notably, this effect was specific for the age of initiation, and was
robust to several possible confounding factors often discussed in
the literature [14, 49]. Furthermore, we provide evidence that an
earlier age of initiation is specifically associated with more severe
positive psychotic symptoms in ROP. The presence of greater
volume in the cerebellar network was associated with reduced
GMV in COI-1, a network mainly comprising the insula, superior
temporal, and inferior frontal gyrus, which has previously been
shown to best discriminate between HC and SZ [9].
The positive association between greater GMV in the
cerebellum and earlier cannabis use initiation is in line with
previous structural imaging studies comparing cannabis-using
and non-using healthy adolescents [50, 51] and young adults
[14, 50–53]. In recent decades the cerebellum has been
increasingly associated with higher cognitive functions, such as
emotion regulation, working memory, and language [54], all of
which undergo substantial evolution during adolescence. Nota-
bly, in the current study, cognition was not associated neither
with cerebellar GMV, nor with age of cannabis initiation. Previous
literature has indicated an impact of cannabis on cognitive
performance, however our findings are in line with meta-analytic
evidence showing the absence of a mediating effect of age of
initiation [55]. Surprisingly, there was no association between the
cerebellar network and cognitive performance [54]. These
unexpectedly negative findings might be due particulars of our
selection of cognitive domains. The cerebellum is amongst the
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neurodevelopmental trajectory, attaining a GMV peak in adoles-
cence, which then declines in early adulthood [54]. A finding of
increased cerebellar volume persisting into adulthood has there-
fore been interpreted to indicate a disturbance of typical brain
maturation, such as failure of synaptic pruning [13, 14, 51].
Remarkably, a twin study of healthy brain development indicates
weaker genetic effects on cerebellar GMV development as
compared to all other brain structures [56]. Hence, it might be
hypothesized that environmental factors play an important role in
shaping cerebellar structure. Cumulative evidence suggests that
these effects might be sex-specific due to a more protracted and
hence more vulnerable cerebellar development in men [54], thus
explaining the increased likelihood for cannabis psychosis in male
(male:female, 4:1) [57]. However, due to the limited sample size,
we cannot exclude that a comparable effect may also be present
in females.
While previous studies often neglected the cerebellum or found
a cerebellar decrease in SZ [58, 59], a recent meta-analytic study
indicates that psychotic patients had greater cerebellar brain
volume as compared to HC [8]. Similarly, individuals at clinical high
risk for psychosis exhibit greater volume in cerebellar regions
compared to HC [32]. Moreover, alterations in these regions
contribute to a brain network predictive for poor psychosocial
functioning [32]. Hence, we suggest that present findings might
indicate an anatomic signature of psychosis either initiated or
exacerbated by early cannabis use.
Surprisingly, we did not find associations between GMV of
frontal networks (COI-2) and the age of cannabis use initiation.
Volumetric decreases in frontal regions and the parahippocampal
gyrus have been associated with an earlier initiation of cannabis
use in healthy individuals [14, 15], and in cannabis-using
adolescents compared to their abstinent peers [18]. The explana-
tion for our negative result for COI-2 might be threefold. First, we
specifically test for an effect of age of cannabis initiation in ROP
patients, in contrast to previous studies potentially detecting
general effects of cannabis use in psychosis. Second, specific
effects of cannabis use during adolescent brain maturation might
differ in vulnerable individuals later presenting with ROP, due to
genetic vulnerability or additional early environmental risk factors
[60]. Third, the use of univariate statistics in previous studies
hindered exploring the highly interconnected nature of the brain.
Despite our negative univariate results, our findings in GMV
covariation, which is thought to reflect shared maturational
processes [23–25], might suggest that this measure is a
particularly important marker of neurodevelopmental
perturbations.
The exploratory network analysis revealed a pathway in which
the cerebellar network bridges the association between the
network that comprises the insula, superior temporal and inferior
frontal gyrus and age of cannabis initiation. Interestingly, greater
GMV in the cerebellar network associated with earlier age of
initiation was in turn associated with decreased GMV in the insula,
superior temporal, and inferior frontal network (COI-1). This latter
network was the most predictive of SZ and includes brain regions
consistently implicated in psychosis [8]. Present findings are
consistent with a model that cannabis consumption during
adolescence causes an excursion from the typical brain matura-
tional process, thereby increasing vulnerability to develop
psychosis later in life. However, causal inferences are fraught,
since it cannot be excluded from cross-sectional studies that
specific GMV patterns may predispose an earlier cannabis
consumption [14], although there is some evidence to the
contrary [50]. Interestingly, stronger positive symptoms were
associated only with an earlier age of initiation, irrespective of
GMV in any brain network, or the duration of the heaviest use. This
finding adds to previous studies showing that adolescent
cannabis use increases the risk of more severe psychotic
symptoms [61, 62]. Moreover, our observation that cannabis use
precedes the onset of attenuated psychotic symptoms indicates
that this effect is directed, as likewise reported elsewhere [63].
We note some limitations of our study. Although we corrected
for inter-scanner effects, some results might yet have been
influenced by differing MRI machines and protocols. This
possibility might be excluded in future studies by balancing
between different sites which would also allow for additional
statistical power in support of methods to correct for any site-
effects [64]. In the network analysis, final edges were included
across most bootstrapped networks, but the resultant network
structure was unstable under subsetting of cases. This instability
could be due to the marginal sample size (N= 102) relative to the
number of nodes analysed (N= 6). Further, network approaches
are typically applied for investigating specific symptoms, such as
PANSS subscores. Again, our sample size calls for some reduction
of variables. All our analyses are cross-sectional, which limits
causal inferences. A longitudinal study design could enable the
investigation of directionality of the neuroanatomic effects of
cannabis use in psychosis, although requiring a logistically difficult
study beginning in early adolescence. Follow-up studies might
Fig. 3 Association between components of interest (COIs), cannabis, and clinical measures. Age of cannabis use initiation, duration of
heaviest use and components (A). Network of identified components, cannabis measures and PANSS positive scale (B). Edges represent partial
correlations between the nodes. Each edge is corrected for all other edges in the network and the scaling of edges in width and color
saturation were adjusted by setting the cut-argument in qgraph to 0.2 [35]. All correlations in the network are negative.
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then investigate the possibly mediating and interacting detri-
mental effects of other risk factors, such as childhood adversity
[65] or inattention-hyperactivity symptoms [66]. Importantly, our
study lacks a control condition of healthy cannabis users. Future
studies might test whether the effects found in the current study
are specific to psychotic patients or represent general effects of
cannabis on the developing brain.
Our GIG-ICA approach indicates that earlier age of cannabis use
initiation among patients with ROP is specifically associated with
increased volume in the same cerebellar network previously
identified in SZ patients. We cautiously attribute this increase in
cerebellar GMV to interference with the trajectory of typical brain
maturation. Additionally, we found evidence that earlier initiation
of cannabis use is associated with more severe psychotic
symptoms in our ROP group. This result calls for more detailed
examination of the interaction between early cannabis use,
neurodevelopment perturbation, and risk of psychosis. Since the
legalization of cannabis products in many countries shall have
unpredictable effects on cannabis consumption in adolescents, it
becomes a matter of vital interest to establish the contribution of
cannabis use to the burden of risk factors for psychosis.
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